• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Scientific Publications by FDA Staff

  • Print
  • Share
  • E-mail

Search Publications



Starting Date

Ending Date

Order by

Entry Details

Blood 2015 Jan 8;125(2):223-8

The intron-22-inverted F8 locus permits intracellular factor VIII synthesis, explaining its low inhibitor risk and suggesting a role for pharmacogenomics.

Sauna ZE, Lozier JN, Kasper CK, Yanover C, Nichols T, Howard TE


Intron-22-inversion (I22I)-patients express the entire FVIII-amino-acid sequence intracellularly as two non-secreted polypeptides and have a positive "intracellular (I)-FVIII-CRM-status". Mutations conferring a positive I-FVIII-CRM-status are associated with low inhibitor-risk and are "pharmacogenetically-relevant" because inhibitor-risk may be affected by the: nature of the therapeutic-FVIII-protein (tFVIII); affinity of any tFVIII-derived-foreign peptide (tFVIII-fp) for any HLA-class-II isomer (HLA-II) comprising individual-MHC-repertoires; and stability of any tFVIII-fp/HLA-II complex. We hypothesize that mutations conferring a completely- or substantially-negative I-FVIII-CRM-status are "pharmacogenetically-irrelevant" because inhibitor-risk is high with any tFVIII and individual-MHC-repertoire.

Category: Journal Article
PubMed ID: #25406352 DOI: 10.1182/blood-2013-12-530113
Includes FDA Authors from Scientific Area(s): Biologics
Entry Created: 2011-10-04 Entry Last Modified: 2015-02-12